Cronbach��s Alpha was 0 72 Awareness of the harm of (secondhand)

Cronbach��s Alpha was 0.72. Awareness of the harm of (secondhand) smoking was measured with two questions ��In the last month, how often, if at all, did you think about the harm your smoking might be doing to you?�� and ��In the last month, how often, if at all, did you think about the harm your smoking might be doing to other people?�� selleckbio (Nagelhout, Van den Putte, et al., 2012). Response categories were ��Never�� (1), ��Rarely�� (2), ��Sometimes�� (3), ��Often�� (4), and ��Very often�� (5). Cronbach��s Alpha was 0.67. Psychosocial Mediators (2008, 2010) Attitudes about quitting were assessed using the question ��If you quit smoking within the next 6 months, this would be���� Respondents could answer on three 5-point scales, whether they thought this would be wise or unwise, pleasant or unpleasant, and positive or negative (Van den Putte, Yzer, Brunsting, & Willemsen, 2005).

Cronbach��s Alpha was 0.87. Subjective norm about quitting was measured with the question ��How do you think that most of the people who are important to you would feel about your quitting smoking within the next 6 months?�� (Van den Putte, Yzer, & Brunsting, 2005). Response categories were ��Strongly disapprove�� (1), ��Disapprove�� (2), ��Neutral�� (3), ��Approve�� (4), ��Strongly approve�� (5). Self-efficacy for quitting was measured using the questions ��Suppose you want to quit smoking within the next 6 months, will you be able to resist smoking when: �� you just woke up?��, ���� you have experienced something annoying?��, ���� you are having a cup of coffee or tea?��, ���� you are drinking alcohol?��, ���� you are offered a cigarette?�� (Hoving, Mudde, & de Vries, 2006).

Response categories were ��I will certainly not be able�� (1), ��I will probably not be able�� (2), ��May be I will be able, may be not�� (3), ��I will probably be able�� (4), and ��I will certainly be able�� (5). Cronbach��s Alpha was 0.88. Intention to quit was assessed with a single question: ��Are you planning to quit smoking: within the next month?�� (4), ���� within the next 6 months?�� (3), �� �� sometime in the future, beyond 6 months�� (2), ���� or are you not planning to quit?�� (1) (De Vries, Mudde, Dijkstra, & Willemsen, 1998). Policy-Relevant Outcomes (2011) Whether respondents had attempted to quit smoking was measured with the question: ��Have you made any attempts to stop smoking since the last survey?�� (Hyland et al.

, 2006). Quit success was assessed by asking respondents who had Cilengitide attempted to quit whether they were back to smoking or still stopped. Respondents who where still stopped or who were back to smoking, but reporting smoking less than once a month, were defined as successful quitters. Respondents who did not attempt to quit, or who were back to smoking more than once a month, were defined as smokers (Hyland et al., 2006).

For example, one study showed that 8 weeks of nicotine patches yi

For example, one study showed that 8 weeks of nicotine patches yielded significantly higher 6-month abstinence rates than did 2 weeks of patches when both were offered to uninsured quitline callers selleck inhibitor (McAfee et al., 2008). However, a study of callers to the New York State Smokers�� Quit Line showed no significant differences in 7-month abstinence rates among those receiving either 2, 4, or 6 weeks of nicotine patches (Cummings et al., 2011). More recently, Ferguson et al. (2012) examined the effect of offering free NRT (vs. no NRT) with either standard or more intensive counseling in a 2 �� 2 factorial design that recruited 2,591 smokers via the English national quitline. Neither the free NRT nor the more intensive counseling improved cessation rates at 6 months postquit.

However, treatment assignment only modestly affected treatment exposure. Actual counseling utilization was similar in the two counseling groups; also, only about half the participants in the NRT group actually obtained the NRT and some participants not offered NRT obtained and used NRT on their own. Thus, the lack of significant effects may be due to functionally similar treatments as well as other methodological differences between studies (McAFee, Fellows, & Zbikowski, 2012). No studies have addressed the relative efficacy of single- agent NRT versus combination NRT among quitline callers. Longer duration NRT and combination NRT boost cessation outcomes in nonquitline studies (Fiore et al., 2008; Piper et al., 2009; Smith et al., 2009; Stead, Perera, Bullen, Mant, & Lancaster, 2008); however, differences between quitline and face-to-face intervention contexts (e.

g., differences in participants, intensity of counseling, and barriers to counseling and research participation) limit generalization of such findings. Moreover, recent data have cast doubt on the effectiveness of cessation pharmacotherapies in real-world use (e.g., Alpert, Connolly, & Biener, 2013; Ferguson et al., 2012), increasing the need to demonstrate effects in conditions that approach such use contexts. There is strong evidence that nonadherence to cessation medication is common among smokers, especially in real-world effectiveness studies (Ossip, Abrams, Mahoney, Sall, & Cummings, 2009; Schmitz, Sayre, Stotts, Rothfleisch, & Mooney, 2005; Wiggers et al., 2006) and is associated with reduced clinical success (Catz et al.

, 2011; Lam, Abdullah, Chan, & Hedley, 2005; Shiffman, Sweeney, Ferguson, Sembower, & Gitchell, 2008). Therefore, this research tested a medication adherence intervention that was designed to address problematic beliefs or knowledge about NRT that might adversely affect appropriate use of the pharmacotherapies. Dacomitinib Thus, the current study tested combination NRT (vs. nicotine patch only), longer duration of NRT (6 vs. 2 weeks), and the medication adherence intervention (vs.

The frequencies of tobacco use, the amount smoked, and perceived

The frequencies of tobacco use, the amount smoked, and perceived bruxism were overall associated as has been reported selleck chemicals earlier (Rintakoski et al., 2010). Independent of genetic background, smoking, and bruxism were associated with identical twin pairs. Further, in the present study, nicotine dependence was associated with more frequent bruxism, even in the presence of a history of major depression and alcohol dependence. The few earlier studies on this topic have all used self-reports of bruxism obtained by questionnaires or interviews for the epidemiological analyses (J. Ahlberg et al., 2004; K. Ahlberg et al., 2005; Johansson et al., 2004; Lavigne et al., 1997; Molina et al., 2001; Ohayon et al., 2001), with a more detailed sleep laboratory examination only in the study of Lavigne et al.

(1997), albeit only on 15 bruxing subjects. Using questionnaires may cause difficulties in defining the actual prevalence of bruxism: It may be even more common among populations than surveys indicate but not recognized as a behavior by individuals because of its potential subconscious nature. However, any underreporting is unlikely to be associated with smoking status or nicotine dependence. It is commonly agreed that sleep bruxism, defined as a stereotyped movement disorder occurring during sleep and characterized by tooth grinding and/or clenching, is in normal subjects detected in about 8% of the adult population (Lavigne, Manzini, & Kato, 2005) The prevalence for bruxism in our study is within the range, as also reported earlier (Hublin et al., 1998).

Bruxism has been associated with stress, anxiety, orofacial pain, and sleep problems. It may also damage teeth and lead to costly treatments. On the other hand, bruxism may as part of sleep arousal mirror reflux disease or sleep apnea (Lavigne et al., 2005). Nevertheless, the pathophysiology of bruxism has remained far from clear. Bruxism has been diagnosed for research purposes using multiple axes: subjective perception by questionnaires and interviews (including a bed partner report of grinding sounds) and objective assessment by extraoral and intraoral examination for secondary clinical signs of bruxism (e.g., masseter hypertrophy, pain on palpation of the masticatory muscles, tooth wear facets, and/or shiny spots on restorations) and/or by electromyographic (EMG) or polysomnographic (PSG) recordings.

Clinical signs of bruxism, however, AV-951 may reflect a problem in the past rather than the present, and even EMG and PSG may only provide a timely indication of a fluctuating phenomenon (Lavigne et al., 2005; Van der Zaag, Lobbezoo, Visscher, Hamburger, & Naeije, 2008). It is commonly accepted that PSG is necessary when physiological events adherent to bruxism episodes are investigated, but it should be borne in mind that most of the epidemiological data on bruxism are gathered from subjects by questionnaire or interview.

However, the FBG level in hepatic steatosis group was significant

However, the FBG level in hepatic steatosis group was significantly higher, supporting the coexistence of dys-regulated glucose metabolism. Previous works found that BMI and TG were independent factors for hepatic steatosis [8], [17] while our findings showed that waist circumference was also DAPT secretase msds associated with hepatic steatosis (Table 3). This result complemented previous findings that BMI and waist circumference were associated with NASH [18]. In addition, we also found uric acid as an independent risk factor for hepatic steatosis, confirming our latest findings that uric acid level was significantly associated with NAFLD [19]. Currently, Entecavir has been confidently considered as first-line monotherapy of CHB, for its potent HBV inhibition ability and a high barrier to resistance [20].

Nevertheless, the effect of anti viral drugs in CHB patients with hepatic steatosis was rarely reported. There was only one article showing none impact of hepatic steatosis on the outcome of peg-��-interferon treatment in CHB patients [21]. Therefore, this study firstly reported the negative effect of hepatic steatosis on Entecavir treatment failure in CHB patients. Such effect is biologically possible, as cellular fat accumulation may decrease the contact area between drugs and hepatocytes, causing reduced bioavailability of Entecavir [22]. Besides, diminished activity of hepatic cytochromes in steatotic hepatocytes may also hamper drug metabolism [23]. In patients with hepatitis C, insulin resistance and obesity coexisted with hepatic steatosis may lead to dysfunction of cellular immune function [24], which might be also true in CHB patients with hepatic steatosis.

To further analyze the association between hepatic steatosis and advanced virological response, we retrospectively separated CHB patients into groups with and without hepatic steatosis and further investigated the overall difference of antiviral effect from 24wk to 96wk. This in-depth analysis showed a significant effect of hepatic steatosis on HBV-DNA clearance and ALT normalization (Table 5). Our finding was of clinical importance as it may change current mode of antiviral therapy in CHB patients with hepatic steatosis. Moreover, it is rational to further investigate the effect of treating hepatic steatosis on HBV antiviral therapy.

We have carried out an RCT (ClinicalTrials: NCT01148576) by Dacomitinib using Entecavir with essentiale or vitamin E to treat CHB patients with hepatic steatosis. Besides, we did a preliminary multivariant analysis on CHB patients without steatosis and found ALT was significantly associated with Entecavir treatment failure at 24wk (p=0.03), in contrast with our previous finding (Table 3). This result supports our hypothesis that hepatic steatosis caused ALT elevation may mask real HBV activation caused ALT elevation. Nevertheless, such association did not show statistic significance at 48wk and 96wk, which needs further study with larger subjects.

Acknowledgments

Acknowledgments Imatinib Mesylate Many thanks are addressed to Dr. Lukas G. Adiossan, Mr. Yao N��Guessan, Ms. Sarah E. Mara, and all the technicians and drivers for their skillful work in the field and the laboratory. Furthermore, we are indebted to the entire Taabo health demographic surveillance system team for their excellent cooperation. Finally, we are deeply grateful for the inhabitants of the selected villages and hamlets for their enthusiastic participation. Funding Statement This study received financial support from the UBS Optimus Foundation. J��rg Utzinger and Giovanna Raso acknowledge financial support from the Swiss National Science Foundation (project no. IZ70Z0_123900 and project no. 32003B_132949/1). Thomas Schmidlin acknowledges financial support from the Swiss Tropical and Public Health Institute (Teaching & Training).

The funders had no role in study design, data collection and analysis, decision to publ
liver fibrosis has long been considered static and irreversible. However, case reports and small cohort studies suggest potential reversibility of liver fibrosis once the pathological trigger is eliminated. Moreover, larger therapeutic studies in patients with chronic hepatitis B or C that were successfully treated with antivirals such as lamivudine and interferon-��, respectively, suggest reversal even in patients with cirrhosis (17, 43). However, these studies have limitations because of biopsy sampling error or small numbers of patients, and the statement that advanced fibrosis (cirrhosis) may reverse has been criticized as premature (11).

Despite the controversies, remarkable progress has been made in the last decade in our understanding of the dynamic nature of liver fibrosis (16, 21, 43), which results from an imbalance of extracellular matrix (ECM) production (fibrogenesis) and its degradation (fibrolysis). Reversibility of liver fibrosis in small rodents is well established (21) although it appears to depend significantly on the degree of preestablished fibrosis and on the particular model. Thus we and others (35) have shown that, despite normalization of profibrogenic gene expression and significant improvement of hepatic architecture and function, collagen content remains unchanged up to 8 wk after toxin withdrawal in thioacetamide (TAA)-induced fibrosis. This contrasts with significant reversal reported in the CCl4 model (22) though reversibility is limited in advanced fibrosis/cirrhosis, possibly attributable to matrix crosslinking (24). In earlier studies, reversibility of secondary biliary fibrosis Batimastat after restoration of bile flow ranged from complete reversal (1) to improvement in liver architecture and function without significant reduction in collagen content (2).

Forced Overexpression of Claudin-3 but not of Claudin-1 Increases

Forced Overexpression of Claudin-3 but not of Claudin-1 Increases the Malignant Potential of HT-29 Cells sellckchem We observed that EGF treatment did not cause statistically significant changes in claudin-1 expression but increased claudin-3 expression concomitantly with the malignant potential in HT-29 cells (Fig. 1B, ,3,3, ,44 and and5).5). Based on these findings, we further examined the effects of the forced claudin-1 and claudin-3 overexpression on cell migration, proliferation and colony formation. Interestingly, we observed that the overexpression of claudin-1 but not that of claudin-3 decreased cell migration (Fig. 7A and 7B). Conversely, cell proliferation was not altered by the overexpression of either claudin at the same time point (Fig. 7C).

Furthermore, we observed increases in the anchorage-dependent and anchorage-independent colonies formation after the overexpression of claudin-3 but not claudin-1 (Fig. 8 and and9,9, respectively). Because claudin-3 overexpression increased the colony formation in HT-29 cells, we assessed whether the forced overexpression of claudin-3 could increase cell proliferation at later time points (24, 48 and 72 h). We verified that claudin-3 overexpression increased cell proliferation at these times (Fig. S2), which could contribute to the increased malignant potential of HT-29 cells. These results indicate that the differential expression of claudins 1 and 3 plays a crucial role in the malignant phenotype of the HT-29 colorectal cancer cells. Figure 7 The effect of claudin-1 and claudin-3 overexpression on migration and proliferation.

Figure 8 The impact of claudin-1 and claudin-3 overexpression on anchorage-dependent colony formation. Figure 9 The impact of claudin-1 and claudin-3 overexpression on anchorage-independent colony formation. Claudin-3 Silencing Prevents the EGF-induced Malignant Potential of HT-29 Cells Because EGF treatment increased claudin-3 expression (Fig. 1B), and the overexpression of this claudin is related to the increased malignant potential of HT-29 Cilengitide cells (Figs. 8 and and9),9), we investigated whether the downregulation of claudin-3 could to prevent the EGF-induced effects in HT-29 cells using claudin-3 siRNA. Using immunoblot analysis, we confirmed a robust downregulation of claudin-3 24 h after transfection using both 25 and 45 nM of claudin-3 siRNA (Fig. 10A). Based on these results, we chose 25 nM of claudin-3 siRNA for subsequent functional analyses. Because claudin-3 overexpression-regulated colony formation is analyzed at late time points (more than 5 days), we evaluated whether the early downregulation of claudin-3 induced by siRNA (at 24 h) would be sufficient to prevent the events regulated by prolonged treatment with EGF.

Mutation analysis showed that the tumor had a KIT exon 11 deletio

Mutation analysis showed that the tumor had a KIT exon 11 deletion at amino acid 552. Twenty-two months after surgery, a liver metastasis was detected on follow-up Nilotinib msds CT scans. The patient was started on imatinib 400 mg/day. The treatment was effective, with a partial response noted after 3 months (Fig. 2A); the treatment was also tolerable, with grade 2 edema the only adverse event experienced by the patient. Fig. 2 Imatinib plasma monitoring.guided dose modification reduced toxicities and maintained response in patient 2. A patient with resected duodenal GIST and a liver metastasis responded to imatinib treatment with a partial response (A; arrows). However, at …

At 26 months following the commencement of imatinib treatment, the patient developed several small, round, mesenteric lymph node enlargements, which were regarded as a sign of disease progression even though the metastatic lesions in his liver remained stable. Imatinib dose was increased to 800 mg/day. After 7 months at this dosage, the patient experienced grade 3 dyspnea and grade 3 pericardial effusion. He was transferred to our clinic for the treatment of these adverse events. However, an in-depth review of his previous serial CT scans by an experienced gastrointestinal radiologist revealed that the morphology of these enlarged mesenteric lymph nodes suggested reactive changes, instead of lymph node metastases, which are rare in GIST (11). The patient was therefore restarted on treatment with 400 mg/day of imatinib. CT scans 10 months later showed that the patient’s liver metastasis were stable (Fig. 2A).

Although his ascites and pleural effusion gradually improved, the patient complained of dyspnea, and diuretics were required for the control of grade 2 generalized edema. Because imatinib plasma monitoring revealed that the patient had high imatinib plasma trough concentrations (3,850 ng/mL and 4,280 ng/mL on two different days; Fig. 2B), we reduced his dose to 300 mg/day, which resulted in imatinib plasma trough concentrations of 2,670 ng/mL and 2,880 ng/mL (Fig. 2B). However, pericardial effusion was persistently observed, even after his imatinib dose was further decreased to 200 mg/day, which resulted in steady-state imatinib plasma trough concentrations of 3,070 ng/mL and 2,710 ng/mL (Fig. 2B). As the patient’s imatinib trough plasma exposure was still sufficiently high (3) and the follow-up CT scan showed that his liver metastasis remained stable (Fig.

2A), we further decreased his dose to 100 mg/day, which resulted in imatinib plasma trough concentrations of 1,660 ng/mL and AV-951 1,480 ng/mL (Fig. 2B). To date, the patient has been taking 100 mg/day of imatinib for approximately 1 yr. His fluid retention has improved, with durable partial response in his liver metastasis. DISCUSSION Imatinib is metabolized in the liver, predominantly by cytochrome P450 (CYP) 3A4 (12).

2) This analysis showed

2). This analysis showed selleck inhibitor that cytokines that were highly abundant in maternal serum, including IL-1��, IL-6, IL-12(p40) and IL-10 (47 to 309pg/100��g of protein), were detected at lower levels (IL-10, 27pg/100��g of protein) or not detected (IL-1��, IL-6 and IL-12(p40)) in fetal brain homogenates. By contrast, cytokines IL-1�� and IL-9 were detected at high levels in fetal brain samples (47 and 109pg/100��g of protein, respectively) while their concentration values were substantially lower in maternal serum (7 and 52pg/100��g of protein, respectively). The ten chemokines assayed were also detected at high concentrations in the maternal serum 6h after poly(I:C) injection (ranging from 65 to 2100pg/100��g of protein), while their concentration values in fetal brain homogenates were below 25pg/100��g of protein (eotaxin, MCP-1 and MIG) or not detected (MIP-1��, RANTES, KC, LIX and MIP-2).

MIP-1�� was the only chemokine found at higher levels in fetal brain homogenates (260pg/100��g of protein) compared with maternal serum (66pg/100��g of protein) and G-CSF concentration in maternal serum reached 2,908pg/100��g of protein while it was below detection limits in fetal brain homogenates. Figure 2 Comparison of immune response-associated soluble factors concentrations between brain homogenates and maternal serum in poly(I:C) treated animals 6h after injection. Values were normalized to total protein content of each tissue. (A) Pro- and … These results indicate that a subset of pro- and anti-inflammatory cytokines and chemokines are normally present in the developing brain and that their expression levels can be modulated directly by poly(I:C) or by the activation of a maternal innate immune response.

However, IRSF expression levels in the prenatal brains do not reflect the changes in concentration levels observed in maternal serum, indicating that IRSF expression GSK-3 is modulated by mechanisms within the embryo or the placenta, and are not a passive consequence of the increase in concentration levels in the maternal serum. Pre and postnatal brains respond differently to poly(I:C) To determine whether changes in IRSF expression levels observed in the fetal brain after poly(I:C) injection were unique to the pregnancy environment or could also be triggered after birth, newborn mice were treated with PBS or poly(I:C) on PND4, and IRSF concentrations were measured in brain homogenates 24h after injection (PND5)(Table (PND5)(Table3).3). As observed in prenatal brain homogenates, a variety of IRSF were detected in control samples, including cytokines IL-1��, IL-2, IL3, IL-6, IL-7, IL-9, IL-13, IL-15, IL-17 and IL-10.

G�CH) Proteins involved in triglyceride metabolism such as DGAT2

G�CH) Proteins involved in triglyceride metabolism such as DGAT2 and PLIN displayed zone 3 to zone 1 distributions. I�CP) Several proteins facilitating phospholipid metabolism, specifically CHKA, PCYT1B, PEMT, PCYT2, GPAT2, PLA2G15, PLA2G4F selleckbio and PLA2B1 all displayed strong zonation. In each instance, except for PCYT2, the strongest staining was in zone 3. (DOCX) Click here for additional data file.(16M, docx) Figure S4 Portal tracts imaged by MALDI-IMS display robust levels of PC 320. Photomicrographs of H&E stained sections from each specimen (A, C, E) and corresponding MALDI IMS images of selected liver specimen obtained from subjects with normal (A�CD) and NASH (E�CF) histologies. (B, D, F) MALDI image of m/z 772.52 PC 320 [M+K]+. Ion intensity color scale for all ion images is shown at the top of the figure.

Scale bar=500 ��m. (DOCX) Click here for additional data file.(2.3M, docx) Table S1 Fragmentation and LC retention time information. (DOCX) Click here for additional data file.(14K, docx) Table S2 Lipids Identified and Quantified in Hepatic Extracts by LC ESI-MS/MS. (DOCX) Click here for additional data file.(18K, docx) Table S3 List of proteins identified in normal human liver and their expression profile in the Human Protein Atlas. (DOCX) Click here for additional data file.(25K, docx) Methods S1 (DOCX) Click here for additional data file.(23K, docx) Acknowledgments The authors thank Dr. Yu Shyr, Vanderbilt Center for Quantitative Sciences, for additional statistical support. We are indebted to Dr.

Kay Washington, Vanderbilt Department of Pathology, for assistance in the pathological assessment of the liver specimens. We are grateful for the guidance and expertise of Dr. David Hachey, Dr. Wade Calcutt and the Vanderbilt Mass Spectrometry Research Center in assisting with nano LC-MS analyses. We thank Dr. Lynne Lapierre, Vanderbilt Epithelial Biology Center, for assistance with immunohistochemistry. We are thankful to Jamie AV-951 Allen, Vanderbilt Mass Spectrometry Research Center, for assistance with sample preparation. We thank Clark M. Murray for assistance in the fragmentation analyses of human tissues and Caleb Huber for assistance in MALDI IMS dataset curation. Fun
We describe a case of moderate hand�Cfoot syndrome and nail toxicity simultaneously occurred in a 69-year-old man with advanced gastric cancer (cT4-N3-M1, G3) previously treated with numerous antineoplastic agents, including PELFw (5-fluorouracil, epidoxorubicin, leucovorin, and cisplatin) and taxoids. Due to a recalcitrant course, the above therapeutic agents were discontinued for 4 weeks and he was given solely capecitabine 1250 mg twice daily for 2 weeks at 3-weekly intervals.

1 �� 3 7) than Whites (14 1 �� 3 6, p < 001) Some limitations o

1 �� 3.7) than Whites (14.1 �� 3.6, p < .001). Some limitations of the study should be noted. White females comprised nearly half of our sample; however, there was no evidence that White females were responsible for the few demographic differences we found in topography. www.selleckchem.com/products/wortmannin.html Indeed, our mean topography data were comparable to those of other studies investigating diverse groups of adolescents (Corrigall et al., 2001; Kassel et al., 2007; Wood et al., 2004; Zack et al., 2001). Another limitation of the study is that adolescents smoked only one cigarette in a laboratory setting after an uncontrolled time since their last cigarette. Thus, we were unable to determine the reliability of the puffing behavior and the extent to which it generalizes to real-world smoking.

A study with adult smokers showed that topography data were consistent across days and that several measures of tobacco exposure were similar when cigarettes were smoked in the laboratory and in the natural environment (Lee et al., 2003). In tobacco-dependent adolescent smokers, we found evidence of regulation of puffing behavior across the smoking of a single cigarette. This suggests that adolescent smokers, like adults, learn early in the dependence process to regulate their smoke and nicotine intake. These results are further confirmation that tobacco dependence is a pediatric disease (Fiore et al., 2008). Funding This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute on Drug Abuse. Declaration of Interests None declared.

Supplementary Material [Article Summary] Click here to view.
Exposure to secondhand smoke (SHS) poses a significant and pervasive health risk to both adults and children (U.S. Department of Health and Human Services [USDHHS], 1986, 2006). As of July 2009, 31 states have promulgated smoke-free air laws that prohibit smoking inside workplaces, bars, and/or restaurants, with 17 of these states having comprehensive laws in effect that require all three of the aforementioned venue types to be 100% smoke free (Americans for Non-Smokers�� Rights [ANR], 2009). However, the implementation and strengthening of these laws has left unregulated areas, including personal living areas, as primary sources of SHS exposure for many individuals.

The Surgeon General��s Call to Action to Promote Healthy Homes emphasizes the importance of instituting smoke-free home policies to reduce involuntary exposure to SHS (USDHHS, 2009). Such policies have also been shown to increase smoking cessation and decrease cigarette consumption in adult smokers (Mills, Messer, Gilpin, & Pierce, 2009). The estimated 80 million Americans who live Anacetrapib in close proximity to one another in multiunit housing (MUH) are particularly susceptible to SHS exposure (Ellis et al., 2009; U.S. Census Bureau [USCB], 2003).